Ken Griffin Immunity Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.32 - $6.7 $12,616 - $25,460	-3,800 Reduced 0.75%	504,700 $1.87 Million
Q2 2024 Aug 14, 2024	SELL	$4.82 - $9.15 $40,488 - $76,860	-8,400 Reduced 1.63%	508,500 $3.21 Million
Q1 2024 May 15, 2024	BUY	$3.23 - $6.17 $516,800 - $987,200	160,000 Added 44.83%	516,900 $2.78 Million
Q4 2023 Feb 14, 2024	BUY	$1.25 - $5.21 $126,375 - $526,731	101,100 Added 39.52%	356,900 $1.79 Million
Q3 2023 Nov 14, 2023	BUY	$1.29 - $3.1 $59,856 - $143,840	46,400 Added 22.16%	255,800 $432,000
Q2 2023 Aug 14, 2023	BUY	$1.53 - $6.41 $191,097 - $800,609	124,900 Added 147.81%	209,400 $582,000
Q1 2023 May 15, 2023	BUY	$1.35 - $4.78 $8,100 - $28,680	6,000 Added 7.64%	84,500 $153,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.77 $5,220 - $8,123	1,200 Added 1.55%	78,500 $397,000
Q3 2022 Nov 14, 2022	BUY	$3.65 - $6.43 $18,980 - $33,436	5,200 Added 7.21%	77,300 $384,000

204

70M

1.68M

1.31M

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.05B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.